150 related articles for article (PubMed ID: 36434947)
21. [Using Immunohistochemical Markers and Clinicopathological Factors to Predict the Prognostic Survival of Different Types of Endometrial Cancer Recurrence].
Huang Z; Jiang P; Jia MZ; Li L; Deng Y; Lai L; Hu ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 May; 52(3):489-496. PubMed ID: 34018370
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Survival After Recurrence in Women With Early-Stage Endometrial Carcinoma.
Xu Y; Burmeister C; Hanna RK; Munkarah A; Elshaikh MA
Int J Gynecol Cancer; 2016 Jul; 26(6):1137-42. PubMed ID: 27206283
[TBL] [Abstract][Full Text] [Related]
23. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
25. Defining prognostic factors in older patients with endometrial cancer.
Yucel Celik O; Unsal M; Kilic F; Unsal P; Aytekin O; Cakir C; Kimyon Comert G; Turkmen O; Turan T
Ir J Med Sci; 2022 Jun; 191(3):1123-1131. PubMed ID: 34101103
[TBL] [Abstract][Full Text] [Related]
26. SATEN III-Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study.
Kahramanoglu I; Meydanli MM; Taranenka S; Ayhan A; Salman C; Sanci M; Demirkiran F; Ortac F; Haidopoulos D; Sukhin V; Kaidarova D; Stepanyan A; Farazaneh F; Aliyev S; Ulrikh E; Kurdiani D; Yalcin İ; Mavrichev S; Akilli H; Sarı ME; Pletnev A; Aslan K; Bese T; Kairbayev M; Vlachos D; Gultekin M
Int J Gynecol Cancer; 2019 Oct; 29(8):1271-1279. PubMed ID: 31481453
[TBL] [Abstract][Full Text] [Related]
27. Analysis of prognostic factors in Grade 3 endometrioid type endometrial carcinoma.
Sahin EA; Toprak S; Sayal HB; Ekinci T; Yılmaz E; Bakay K; Melekoğlu R; Sezgin B; Tohma YA; Şahin H
Int J Gynaecol Obstet; 2022 Dec; 159(3):719-726. PubMed ID: 35598153
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer.
Yerramilli D; Chen YH; Venkatachalam V; Alban GM; Buscariollo DL; Cheng T; King MT; Pretz JL; Russo AL; Lee LJ
Pract Radiat Oncol; 2021; 11(5):394-403. PubMed ID: 34015544
[TBL] [Abstract][Full Text] [Related]
29. Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort.
Farrell R; Dixon SC; Carter J; Webb PM
Int J Gynecol Cancer; 2017 Sep; 27(7):1379-1386. PubMed ID: 30814240
[TBL] [Abstract][Full Text] [Related]
30. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
31. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma.
Swift BE; Covens A; Mintsopoulos V; Parra-Herran C; Bernardini MQ; Nofech-Mozes S; Hogen L
Int J Gynecol Cancer; 2022 Apr; 32(4):525-531. PubMed ID: 34969829
[TBL] [Abstract][Full Text] [Related]
32. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
33. Lymphadenectomy and prognosis for elderly females with stage I endometrioid endometrial cancer.
Zhao L; Li L; Ye Y; Han X; Fu X; Yu Y; Luo J
Arch Gynecol Obstet; 2019 Sep; 300(3):683-691. PubMed ID: 31256231
[TBL] [Abstract][Full Text] [Related]
34. Vaginal and pelvic recurrences in stage I and II endometrial carcinoma--survival and prognostic factors.
Blecharz P; Brandys P; Urbański K; Reinfuss M; Patla A
Eur J Gynaecol Oncol; 2011; 32(4):403-7. PubMed ID: 21941962
[TBL] [Abstract][Full Text] [Related]
35. Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer.
Weinberg LE; Kunos CA; Zanotti KM
Int J Gynecol Cancer; 2013 Oct; 23(8):1438-45. PubMed ID: 24257558
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analysis of prognostic variables and clinical outcomes in surgically staged intermediate risk endometrial carcinoma.
Zhang GY; Wu LY; Li B; Huang MN; Zhang R; Li XG
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):309-16. PubMed ID: 23540792
[TBL] [Abstract][Full Text] [Related]
37. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
[TBL] [Abstract][Full Text] [Related]
38. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
39. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
Kim TH; Kim HS; Kim TJ; Chang SJ; Kim DY; Ryu SY; Kim BG; Kim YT; Bae DS; Ryu HS; Nam JH
Gynecol Oncol; 2016 Jun; 141(3):440-446. PubMed ID: 27020700
[TBL] [Abstract][Full Text] [Related]
40. Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
Reijntjes B; van Suijlichem M; Woolderink JM; Bongers MY; Reesink-Peters N; Paulsen L; van der Hurk PJ; Kraayenbrink AA; Apperloo MJA; Slangen B; Schukken T; Tummers FHMP; van Kesteren PJM; Huirne JAF; Boskamp D; Lunter G; de Bock GH; Mourits MJE
Gynecol Oncol; 2022 Feb; 164(2):265-270. PubMed ID: 34955237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
